Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MHLW

- PMLiVE

Daily Brief: DeepMind and NHS success in AI, Bayer invests in COPD, Alecensa OK in Scotland

The latest from pharma, biotech and healthcare

Bayer symbol

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment

Biomarin

BioMarin ups the ante for pivotal haemophilia gene therapy trial

Adds another 90 patients to the GENEr8-1 registration study

- PMLiVE

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

Latest data could unlock a new patient population for the Swiss pharma giant’s injection

- PMLiVE

Shaping healthcare

Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes

Bayer looks to leverage AI across the pharma value chain

Dieter Weinand outlines his hopes for applying artificial intelligence

Roche Basel Switzerland

Roche wins European approval for bleeding disorder treatment Hemlibra

It's the first new medicine in over 20 years to treat patients with inhibitors

- PMLiVE

Pharma sales help Bayer escape the worst from a bumpy 2017

But the German pharma firm reins in expectations for this year

Working with our healthcare system more closely is vital

Bayer’s Lars Bruening on partnership working amid environmental challenges

Roche Basel Switzerland

Roche wins CHMP backing for Hemlibra

Haemophilia A treatment on course for European approval

- PMLiVE

Shire claims EU approval for haemophilia A drug Adynovi

The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links